Baxter International - BAX Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $46.30
Forecasted Upside: 17.30%
Number of Analysts: 9
Breakdown:
0 Sell Ratings
7 Hold Ratings
2 Buy Ratings
0 Strong Buy Ratings

^$39.47 As of 04/19/2024 01:00 AM ET

▼ -0.18 (-0.45%)

1 month | 3 months | 12 months

Get New Baxter International Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BAX

^$46.30

▲ +17.30% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Baxter International in the last 3 months. The average price target is $46.30, with a high forecast of $56.00 and a low forecast of $36.00. The average price target represents a 17.30% upside from the last price of $39.47.

Current Consensus is Hold

The current consensus among 9 polled investment analysts is to hold stock in Baxter International. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
2 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

10/27/2022

0 strong buy ratings
2 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

1/25/2023

0 strong buy ratings
2 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

4/25/2023

0 strong buy ratings
2 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

7/24/2023

0 strong buy ratings
2 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

10/22/2023

0 strong buy ratings
2 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

1/20/2024

0 strong buy ratings
2 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

3/20/2024

0 strong buy ratings
2 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

4/19/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/3/2024	Citigroup	Boost Target	Neutral ➝ Neutral	$41.00 ➝ $44.00	Low
3/5/2024	Bank of America	Boost Target	Neutral ➝ Neutral	$42.00 ➝ $45.00	Low
2/12/2024	Barclays	Boost Target	Overweight ➝ Overweight	$52.00 ➝ $54.00	Low
2/9/2024	JPMorgan Chase & Co.	Boost Target	Neutral ➝ Neutral	$38.00 ➝ $44.00	Low
2/6/2024	UBS Group	Lower Target	Neutral ➝ Neutral	$40.00 ➝ $36.00	Low
12/4/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$45.00 ➝ $39.00	Low
10/31/2023	JPMorgan Chase & Co.	Lower Target	Neutral ➝ Neutral	$49.00 ➝ $36.00	Low
10/24/2023	Deutsche Bank Aktiengesellschaft	Boost Target	Hold ➝ Hold	$35.00 ➝ $50.00	Low
10/2/2023	Citigroup	Lower Target		$45.00 ➝ $41.00	Low
8/21/2023	Citigroup	Lower Target	Neutral ➝ Neutral	$47.00 ➝ $45.00	Low
7/31/2023	KeyCorp	Lower Target	Overweight	$53.00 ➝ $51.00	Low
7/31/2023	Barclays	Lower Target	Overweight ➝ Overweight	$58.00 ➝ $54.00	Low
7/28/2023	Wells Fargo & Company	Lower Target	Equal Weight	$46.00 ➝ $44.00	Low
7/12/2023	Stifel Nicolaus	Boost Target		$54.00 ➝ $56.00	Low
5/30/2023	888	Reiterated Rating	Assumes		Low
5/1/2023	Barclays	Boost Target		$54.00 ➝ $58.00	Low
4/28/2023	Stifel Nicolaus	Boost Target		$45.00 ➝ $54.00	Low
4/28/2023	Deutsche Bank Aktiengesellschaft	Boost Target		$40.00 ➝ $50.00	Low
4/28/2023	KeyCorp	Boost Target		$52.00 ➝ $53.00	Low
4/4/2023	Evercore ISI	Lower Target	Outperform	$50.00 ➝ $48.00	Low
3/28/2023	UBS Group	Initiated Coverage	Neutral	$43.00	Low
2/13/2023	Citigroup	Lower Target	Neutral	$58.00 ➝ $44.00	Low
2/13/2023	Barclays	Lower Target	Overweight	$63.00 ➝ $54.00	Low
2/10/2023	Wells Fargo & Company	Lower Target	Equal Weight	$52.00 ➝ $43.00	Low
2/10/2023	Morgan Stanley	Lower Target	Equal Weight	$55.00 ➝ $44.00	Low
2/10/2023	Cowen	Lower Target	Outperform	$70.00 ➝ $45.00	Low
2/6/2023	KeyCorp	Lower Target	Overweight	$73.00 ➝ $60.00	Low
1/9/2023	Wells Fargo & Company	Lower Target	Equal Weight	$57.00 ➝ $52.00	Low
1/6/2023	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$55.00	Low
1/5/2023	Raymond James	Downgrade	Outperform ➝ Market Perform		N/A
1/4/2023	Barclays	Lower Target		$64.00 ➝ $63.00	Low
1/3/2023	Bank of America	Downgrade	Buy ➝ Neutral	$66.00 ➝ $55.00	Low
12/19/2022	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$68.00 ➝ $55.00	Low
12/15/2022	Wells Fargo & Company	Lower Target	Equal Weight	$59.00 ➝ $57.00	Low
12/15/2022	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold	$69.00 ➝ $51.00	Low
12/12/2022	Citigroup	Downgrade	Buy ➝ Neutral	$64.00 ➝ $58.00	Low
11/3/2022	The Goldman Sachs Group	Lower Target	Sell	$60.00 ➝ $53.00	Low
10/28/2022	Raymond James	Lower Target	Outperform	$66.00 ➝ $61.00	Low
10/28/2022	Wells Fargo & Company	Lower Target	Equal Weight	$63.00 ➝ $59.00	Low
10/28/2022	KeyCorp	Lower Target	Overweight	$77.00 ➝ $73.00	Low
10/17/2022	Barclays	Initiated Coverage	Overweight	$64.00	Low
10/12/2022	Jefferies Financial Group	Initiated Coverage	Hold	$62.00	Low
10/11/2022	Morgan Stanley	Lower Target	Overweight	$72.00 ➝ $70.00	Low
10/5/2022	Citigroup	Lower Target		$74.00 ➝ $70.00	Low
8/3/2022	The Goldman Sachs Group	Reiterated Rating	Sell	$70.00 ➝ $60.00	Low
7/29/2022	Cowen	Lower Target		$95.00 ➝ $70.00	Low
7/29/2022	Cowen	Lower Target		$95.00 ➝ $70.00	Low
7/29/2022	Deutsche Bank Aktiengesellschaft	Lower Target		$99.00 ➝ $69.00	Low
7/29/2022	Morgan Stanley	Lower Target	Overweight	$86.00 ➝ $72.00	Low
7/28/2022	Citigroup	Lower Target		$82.00 ➝ $74.00	Low
7/18/2022	Stifel Nicolaus	Lower Target		$85.00 ➝ $75.00	Low
7/15/2022	Morgan Stanley	Lower Target	Overweight	$95.00 ➝ $86.00	Low
6/24/2022	JPMorgan Chase & Co.	Lower Target	Overweight	$90.00 ➝ $78.00	Low
6/24/2022	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$71.00	Low
5/23/2022	Morgan Stanley	Lower Target	Overweight	$100.00 ➝ $95.00	Low
5/17/2022	Citigroup	Lower Target	Buy	$98.00 ➝ $85.00	N/A
4/29/2022	Raymond James	Lower Target		$96.00 ➝ $85.00	Low
4/4/2022	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$88.00 ➝ $77.00	High
3/1/2022	Bank of America	Initiated Coverage	Buy ➝ Buy	$100.00	Low
2/18/2022	Wells Fargo & Company	Lower Target	Overweight	$95.00 ➝ $93.00	High
2/18/2022	Stifel Nicolaus	Boost Target	Buy	$90.00 ➝ $91.00	High
2/18/2022	UBS Group	Boost Target	Neutral ➝ Neutral	$88.00 ➝ $91.00	Low
2/18/2022	Morgan Stanley	Lower Target	Overweight	$110.00 ➝ $105.00	Low
2/18/2022	Raymond James	Lower Target	Outperform	$99.00 ➝ $96.00	Low
2/18/2022	KeyCorp	Lower Target	Overweight	$98.00 ➝ $95.00	Medium
2/11/2022	The Goldman Sachs Group	Initiated Coverage	Neutral	$91.00	Medium
1/7/2022	Citigroup	Initiated Coverage	Buy	$101.00	Low
1/7/2022	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$86.00 ➝ $110.00	Low
1/4/2022	Raymond James	Boost Target	Outperform	$93.00 ➝ $99.00	High
1/4/2022	KeyCorp	Boost Target	Overweight	$92.00 ➝ $98.00	High
12/17/2021	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight		Medium
10/29/2021	Morgan Stanley	Lower Target	Equal Weight	$90.00 ➝ $86.00	High
9/21/2021	Raymond James	Initiated Coverage	Buy	$93.00	Low
9/13/2021	Cowen	Upgrade	Market Perform ➝ Outperform	$98.00	Low
9/5/2021	SVB Leerink	Reiterated Rating	Buy		Low
9/3/2021	Barclays	Upgrade	Equal Weight ➝ Overweight	$93.00 ➝ $100.00	Low
8/3/2021	The Goldman Sachs Group	Lower Target	Neutral	$93.00 ➝ $80.00	Low
8/2/2021	KeyCorp	Lower Target	Overweight	$94.00 ➝ $92.00	Low
7/29/2021	Stifel Nicolaus	Lower Target	Buy	$95.00 ➝ $90.00	Low
7/29/2021	Piper Sandler	Lower Target	Neutral	$85.00 ➝ $82.00	Low
5/24/2021	Barclays	Initiated Coverage	Equal Weight	$93.00	Low
4/30/2021	Citigroup	Boost Target		$94.00 ➝ $98.00	Low
4/29/2021	Piper Sandler	Boost Target	Neutral ➝ In-Line	$80.00 ➝ $85.00	Low
3/18/2021	Oppenheimer	Reiterated Rating	Buy		Low
2/5/2021	Credit Suisse Group	Lower Target	Outperform	$99.00 ➝ $95.00	Low
2/5/2021	Raymond James	Lower Target	Outperform	$88.00 ➝ $85.00	Low
1/29/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral	$100.00 ➝ $80.00	Low
1/6/2021	UBS Group	Downgrade	Buy ➝ Neutral	$95.00 ➝ $85.00	N/A
12/15/2020	Morgan Stanley	Boost Target	Equal Weight	$84.00 ➝ $90.00	Low
12/15/2020	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$96.00 ➝ $85.00	Medium
11/2/2020	Stifel Nicolaus	Lower Target	Buy	$90.00 ➝ $88.00	Low
10/30/2020	Morgan Stanley	Lower Target	Equal Weight	$90.00 ➝ $84.00	Low
10/30/2020	KeyCorp	Lower Target	Overweight	$98.00 ➝ $94.00	Low
10/12/2020	Raymond James	Lower Target	Outperform	$95.00 ➝ $88.00	Low
10/9/2020	UBS Group	Lower Target	Buy	$98.00 ➝ $96.00	Medium
10/1/2020	Citigroup	Upgrade	Neutral ➝ Buy	$94.00	Medium
9/4/2020	Argus	Downgrade	Buy ➝ Hold		Medium
8/11/2020	Credit Suisse Group	Reiterated Rating	Buy	$99.00	Low
7/31/2020	Credit Suisse Group	Reiterated Rating	Buy	$99.00	High
7/31/2020	Raymond James	Lower Target	Outperform	$97.00 ➝ $95.00	Medium
7/31/2020	Morgan Stanley	Lower Target	Equal Weight	$95.00 ➝ $90.00	Low
7/30/2020	Oppenheimer	Reiterated Rating	Buy		Low
6/23/2020	Oppenheimer	Initiated Coverage	Outperform	$100.00	Medium
5/1/2020	UBS Group	Boost Target	Buy	$95.00 ➝ $103.00	Low
5/1/2020	SVB Leerink	Boost Target	Outperform	$96.00 ➝ $105.00	Low
5/1/2020	Credit Suisse Group	Boost Target	Outperform	$97.00 ➝ $99.00	Low
5/1/2020	KeyCorp	Boost Target	Overweight	$92.00 ➝ $98.00	Low
4/30/2020	Piper Sandler	Boost Target	Overweight	$90.00 ➝ $100.00	Low
4/28/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$94.00 ➝ $96.00	Low
4/20/2020	Wells Fargo & Company	Boost Target	Overweight	$92.00 ➝ $104.00	Low
4/14/2020	Barclays	Reiterated Rating	Hold	$84.00	High
4/13/2020	Raymond James	Boost Target	Outperform	$90.00 ➝ $97.00	Low
4/2/2020	Wells Fargo & Company	Reiterated Rating	Buy		High
3/27/2020	Morgan Stanley	Boost Target	Hold	$88.00 ➝ $95.00	Low
3/19/2020	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$87.00 ➝ $95.00	High
3/18/2020	Wells Fargo & Company	Lower Target		$102.00 ➝ $95.00	High
3/18/2020	Deutsche Bank Aktiengesellschaft	Lower Target	Buy	$109.00 ➝ $99.00	High
3/18/2020	Citigroup	Lower Target	Neutral	$94.00 ➝ $89.00	High
3/18/2020	Credit Suisse Group	Lower Target	Outperform	$98.00 ➝ $96.00	High
3/18/2020	Raymond James	Lower Target	Neutral ➝ Outperform	$95.00 ➝ $90.00	High
3/18/2020	KeyCorp	Upgrade	Sector Weight ➝ Overweight	$92.00	High
3/17/2020	SVB Leerink	Reiterated Rating	Outperform		High
3/6/2020	Credit Suisse Group	Boost Target	Outperform	$95.00 ➝ $98.00	Medium
3/4/2020	Citigroup	Initiated Coverage	Neutral	$94.00	High
2/14/2020	Wells Fargo & Company	Boost Target	Overweight	$100.00 ➝ $102.00	Low
2/12/2020	The Goldman Sachs Group	Initiated Coverage	Buy	$104.00	Low
2/6/2020	Cfra	Boost Target	Hold	$87.00 ➝ $93.00	Low
1/16/2020	Wells Fargo & Company	Boost Target	Overweight	$95.00 ➝ $100.00	Low
1/13/2020	UBS Group	Reiterated Rating	Buy	$102.00	High
1/2/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight		High
1/2/2020	Citigroup	Upgrade	Neutral ➝ Buy		High
1/2/2020	Evercore ISI	Upgrade	In-Line ➝ Outperform	$80.00 ➝ $94.00	High
12/20/2019	JPMorgan Chase & Co.	Boost Target	Overweight	$89.00 ➝ $94.00	Low
12/17/2019	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$90.00 ➝ $88.00	Medium
10/21/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$109.00	High
10/8/2019	JPMorgan Chase & Co.	Set Target	Buy	$94.00	Low
9/10/2019	Piper Sandler Companies	Reiterated Rating	Buy		N/A
7/26/2019	Royal Bank of Canada	Set Target	Hold	$87.00	Low
7/26/2019	Barclays	Set Target	Hold	$82.00	Low
7/26/2019	Wells Fargo & Company	Set Target	Buy	$95.00	Low
7/26/2019	Raymond James	Boost Target	Outperform	$84.00 ➝ $95.00	Low
7/26/2019	Credit Suisse Group	Boost Target	Reduce ➝ Outperform	$84.00 ➝ $95.00	Low
7/26/2019	BMO Capital Markets	Boost Target	Outperform	$95.00	Low
7/25/2019	Piper Sandler Companies	Boost Target	Overweight	$90.00 ➝ $95.00	Low
6/26/2019	Wells Fargo & Company	Boost Target	Outperform	$89.00 ➝ $91.00	Low
6/25/2019	KeyCorp	Initiated Coverage	Sector Weight ➝ Sector Weight		Medium
6/20/2019	Piper Sandler Companies	Boost Target	Overweight	$80.00 ➝ $90.00	Low
5/13/2019	JPMorgan Chase & Co.	Boost Target	Overweight	$80.00 ➝ $88.00	Low
4/22/2019	Cowen	Set Target	Hold	$75.00	Low

(Data available from 4/20/2019 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

11 very positive mentions
16 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

9/23/2023

12 very positive mentions
13 positive mentions
4 negative mentions
3 very negative mentions

Mentions as of

10/23/2023

9 very positive mentions
16 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

11/22/2023

9 very positive mentions
17 positive mentions
4 negative mentions
3 very negative mentions

Mentions as of

12/22/2023

3 very positive mentions
11 positive mentions
4 negative mentions
1 very negative mentions

Mentions as of

1/21/2024

20 very positive mentions
20 positive mentions
4 negative mentions
5 very negative mentions

Mentions as of

2/20/2024

12 very positive mentions
22 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

3/21/2024

12 very positive mentions
23 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

4/20/2024

Current Sentiment

Recent Stories by Sentiment

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Today's Range

Now: $39.47

$39.39

$40.08

50 Day Range

MA: $41.80

$39.47

$43.77

52 Week Range

Now: $39.47

$31.01

$50.21

Volume

2,788,110 shs

Average Volume

3,103,316 shs

Market Capitalization

$20.04 billion

P/E Ratio

7.56

Dividend Yield

2.93%

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Baxter International?: The following Wall Street research analysts have issued research reports on Baxter International in the last year: 888 Holdings plc, Bank of America Co., Barclays PLC, Citigroup Inc., Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., KeyCorp, Morgan Stanley, Stifel Nicolaus, StockNews.com, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for BAX.
What is the current price target for Baxter International?: 10 Wall Street analysts have set twelve-month price targets for Baxter International in the last year. Their average twelve-month price target is $46.30, suggesting a possible upside of 17.3%. Stifel Nicolaus has the highest price target set, predicting BAX will reach $56.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $36.00 for Baxter International in the next year.
View the latest price targets for BAX.
What is the current consensus analyst rating for Baxter International?: Baxter International currently has 7 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BAX, but not buy more shares or sell existing shares.
View the latest ratings for BAX.
What other companies compete with Baxter International?: Other companies that are similar to Baxter International include ResMed, Insulet, Teleflex, Globus Medical and DexCom. Learn More about companies similar to Baxter International.
How do I contact Baxter International's investor relations team?: Baxter International's physical mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The medical instruments supplier's listed phone number is (224) 948-2000 and its investor relations email address is [email protected]. The official website for Baxter International is www.baxter.com. Learn More about contacing Baxter International investor relations.

Baxter International - BAX Stock Price Target and Predictions

Analyst Price Target for BAX

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.51 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Baxter International?

What is the current price target for Baxter International?

What is the current consensus analyst rating for Baxter International?

What other companies compete with Baxter International?

How do I contact Baxter International's investor relations team?